- Poster presentation
- Open Access
Molecular adsorbent recirculating system in patients with acute liver failure: prospective follow-up
© BioMed Central Ltd. 2010
- Published: 1 March 2010
- Liver Transplantation
- Liver Failure
- Serum Creatinine Level
- Bilirubin Level
- Prospective Observational Study
A prospective observational study on molecular adsorbent recirculating system (MARS) therapy in a liver-disease-dedicated ICU.
From January 2004 to November 2009, all patients with an acute liver failure fulfilling MARS therapy criteria, in relation to two main indications: primary and secondary to chronic liver failure (ALF/ACLF = group 1) or intractable pruritus (IP = group 2), were included: Data were collected before and after each MARS procedure. APACHE and MELD scores  were used to predict the ICU mortality and the 90-day mortality, respectively.
MARS therapy improves liver function in patients with both acute and chronic liver failure, and allows those patients to wait until OLT, if necessary. Furthermore it also improves the 90-day survival of patients with ACLF having no OLT indication.